Navigation Links
Embolic Protection Devices (EPD) - Emerging Markets 2009-2015
Date:11/7/2013

DUBLIN, Ireland, November 7, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/qfnpf3/embolic) has announced the addition of the "Embolic Protection Devices (EPD) - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015" report to their offering.

BRICSS EP Devices market forecasts to reach at US$93.3 million by 2015 at a CAGR of 15.6% during the analysis period 2009-2015. China accounts for nearly 30% of the global value and India claims around 20% of the market. In terms of CAGR, India is the fastest growing regions while China, South Korea and Russia are just behind. Forecasts for balloon occlusion types indicate a close 47% of the market value while catheters occlusion devices account for nearly 40%. In case of procedures, coronary sector depicts the largest CAGR while peripheral artery and neurology segments come in second and third place respectively.

Publication Overview

The report Embolic Protection Devices (EPD) - Emerging Markets (Brazil, Russia, India, China, South Africa and South Korea), 2009-2015' reviews the latest trends in the EPD market with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations.

The report primarily focuses on:

- Emerging Market Trends
- Advancements in the Technological Space
- Market Demand Of The Segments (By-Region)
- Key Growth Areas and Market Size
- Region-Wise Demand Factor
- Key Competitors Edge
- Investment Strategies

The report covers the market analysis by product types and by procedures. The subdivisions are as:

- By Product
a. Balloon Occlusion Devices
b. Catheter Occlusion Devices
c. Filter Devices

- By Procedures
a. Carotid/Neurology
b. Coronary
c. Peripheral Artery

Companies Mentioned

- Abbott Vascular Devices
- Abiomed
- Advansource Biomaterials
- Aga Medical Corporation
- Atrium Medical Corp.
- Ats Medical
- Biophan Technologies
- Biosense Webster
- Boston Scientific Corp.
- Cardiac Science Corp.
- Cardiacassist
- Cardica
- Cardiomems
- Cook Group Incorporated
- Cordis Corporation
- Cryolife
- Idev Technologies
- Medtronic

... and many more.

For more information visit http://www.researchandmarkets.com/research/qfnpf3/embolic

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Devices



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
2. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
3. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
4. Peripheral Vascular Devices Market (Peripheral Vascular Stents, PTA Balloon Catheters, Guidewires, IVC Filters, Atherectomy, Chronic Total Occlusion, Embolic Protection Devices, Synthetic Surgical Grafts, Aortic Stents) - Global Industry Analysis, S
5. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
6. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
7. Study: Surefire Medicals Technology Improves Delivery Of Embolics In Cancer Treatment
8. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
9. TSI Respiratory Protection Roadshow Rated Top-Notch By Attendees
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. iBio Obtains New IP Protection in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... 23, 2017 ReNeuron reported in December ... in chronic stroke patients, despite not meeting the three-month time ... the Action Research Arm Test (ARAT). As a result, the ... controlled clinical study in 2017. Beyond CTX, we expect safety ... 2017 and Phase I data from its critical limb ischaemia ...
Breaking Medicine Technology:
(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
Breaking Medicine News(10 mins):